UCLA Health

Weight gain is common in people with HIV after starting HIV treatment. Obesity while taking HIV medication increases the risk for diabetes, heart disease and stroke. People who are taking certain medications (such as Tivicay, Issentress or one of the drugs contained in Biktarvy) combined with tenofovir alafenamide (TAF) may be more overweight than people taking other drug combinations. The purpose of this study (A5391) is to see whether people with HIV can either slow their weight gain or even lose weight by switching to different HIV medications that are shown to be as effective at controlling HIV.

Eligibility:

  • ≥ 18 years of age
  • HIV positive
  • Overweight (BMI ≥ 30 kg/m)
  • On continuous HIV treatment for at least 48 weeks
  • Undetectable viral load for at least 48 weeks

For more information about A5391, please contact our study team at 310-843-2015 or CAREOUTREACH@mednet.ucla.edu.